Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPH1 | P17752 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | PARP1 | P09874 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | HTR2B | P41595 | 9/20 | 0.53 |
| ▸ | HTR7 | P34969 | 7/20 | 0.53 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27489015 | 0.98 | TPH1 (0.53) | TPH1CYP2C19POLBCYP3A4PARP1 | |
| Hydrochloric Acid SCHEMBL27296270 | 0.98 | TPH1 (0.53) | TPH1CYP2C19POLBCYP3A4PARP1 | |
| Hydrochloric Acid SCHEMBL27319279 | 0.98 | TPH1 (0.53) | TPH1CYP2C19POLBCYP3A4PARP1 | |
| SCHEMBL5441718 | 0.87 | SLC9A1 (0.53) | TPH1MAPTHTR2BHTR7SLC9A1 | |
| Hydrochloric Acid SCHEMBL7824640 | 0.86 | SLC9A1 (0.51) | TPH1MAPTHTR2BHTR7SLC9A1 | |
| SCHEMBL17008170 | 0.84 | POLB (0.52) | CYP2C19POLBCYP3A4PARP1MAPT | |
| SCHEMBL1387930 | 0.82 | KMO (0.56) | HTR2BHTR7SLC9A1DRD2ADRA1D | |
| SCHEMBL5434684 | 0.82 | PARP10 (0.65) | TPH1HTR2BHTR7SLC9A1 | |
| SCHEMBL15320289 | 0.82 | CYP2C19 (0.50) | TPH1CYP2C19POLBCYP3A4PARP1 | |
| SCHEMBL15336489 | 0.82 | CYP2C19 (0.50) | TPH1CYP2C19POLBCYP3A4PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1355 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4577202-A1 | USE OF A THERAPEUTIC AGENT WITH SODIUM-HYDROGEN ANTIPORTER 1 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | Mitodicure GmbH (DE) | 2025-07-02 | — | — | EP | claimed |
| CN-119923254-A | Use of therapeutic agents having sodium hydrogen antiport 1 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or fatigue intolerance | 米托迪治愈有限责任公司 | 2025-05-02 | — | — | CN | claimed |
| WO-2024042160-A1 | USE OF A THERAPEUTIC AGENT WITH SODIUM-HYDROGEN ANTIPORTER 1 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | MITODICURE GMBH (DE) | 2024-02-29 | — | — | WO | claimed |
| CN-115317474-A | Application of benzoylguanidine derivative in preparation of medicine for preventing and treating nervous system diseases or cardiovascular system diseases | 中国海洋大学 | 2022-11-11 | — | — | CN | claimed |
| US-10472332-B2 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2019-11-12 | — | — | US | claimed |
| US-20170260147-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2017-09-14 | — | — | US | claimed |
| US-20150313909-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2015-11-05 | — | — | US | claimed |
| CN-104447623-A | Compound capable of protecting myocardium from ischemia reperfusion injury and application of compound | UNIV PLA 2ND MILITARY MEDICAL | 2015-03-25 | — | — | CN | claimed |
| US-20130217707-A1 | TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER WITH NHE INHIBITORS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2013-08-22 | — | — | US | claimed |
| EP-2617709-A1 | Guanidine derivatives as antiviral agents | Biotron Limited (AU) | 2013-07-24 | — | — | EP | claimed |
| EP-0589336-A1 | Benzoylguanidines, process for their preparation and their use as antiarrhythmic agents | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-03-30 | — | — | EP | claimed |
| US-5292755-A | USPA benzolyguanidines | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-03-08 | — | — | US | claimed |
| EP-0577024-A1 | 3,4,5 substituted benzoylguanidines, process for their preparation, their use as medicament or diagnostic agent, as well as a medicament containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-01-05 | — | — | EP | claimed |
| CN-1075960-A | Amino benzoyl guanidine, its preparation method that replaces is as the purposes and the medicament that contains it of medicine | HOECHST AG (DE) | 1993-09-08 | — | — | CN | claimed |
| EP-0556673-A1 | Ortho-substituted benzoylguanidines for the treatment and prophylaxis of heart-rhythm disorders and ischaemically induced damage, as well as inhibition of cell proliferation | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-08-25 | — | — | EP | claimed |
| EP-0556672-A1 | Amino-substituted benzoylguanidines with antiarrhythmic properties | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-08-25 | — | — | EP | claimed |
| EP-0556674-A1 | 3,5-substituted benzoylguanidines with antiarrhythmic activity and cell proliferation inhibiting activity | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-08-25 | — | — | EP | claimed |
| US-5091394-A | BENZOYLGUANIDINES, A PROCESS FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND MEDICAMENTS CONTAINING THEM | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-02-25 | — | — | US | claimed |
| CN-1050018-A | Benzoylguanidines, they the preparation method, they are as the application of medicament and the medicament that contains them | HOECHST AG (DE) | 1991-03-20 | — | — | CN | claimed |
| EP-0416499-A2 | Benzoylguanidines, process for their preparation, their use as medicaments as well as medicament containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-03-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10472332-B2 | Antiviral compounds and methods | MAVS, ZC3HAV1, EIF2AK2 | TPH1 2424/4885CYP2C19 3582/4885POLB 66/4885 |
| US-20170260147-A1 | ANTIVIRAL COMPOUNDS AND METHODS | MAVS, ZC3HAV1, EIF2AK2 | TPH1 2424/4885CYP2C19 3582/4885POLB 66/4885 |
| US-20150313909-A1 | ANTIVIRAL COMPOUNDS AND METHODS | ZC3HAV1, MAVS, EIF2AK2 | TPH1 2496/4885CYP2C19 3472/4885POLB 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.